Citi Appointed as Depositary Bank for Innate Pharma’s ADR Programme
Citi, acting through Citibank N.A., has been appointed by Innate Pharma S.A – a commercial stage oncology-focused biotech company – to act as depositary bank for its American Depositary Receipt (“ADR”) programme.
Innate Pharma’s American Depositary Shares (“ADS”) trade on the Nasdaq Global Select Market under the symbol “IPHA”. Each ADS represents one ordinary share of the company. Innate Pharma’s underlying ordinary shares are listed and trade on Euronext Paris under the symbol “IPH”.'
Commenting on the appointment, Dirk Jones, Global Head of Issuer Services, at Citi said: “We look forward to supporting Innate Pharma’s Nasdaq listed ADR programme and further expand the company’s investor outreach through the expertise of our leading Investor Relations Advisory team and the breadth of our global equity distribution network.”
